The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.
 
Sarah Danson
Consulting or Advisory Role - Orion; Oxcia
Research Funding - Amgen - Local PI; Artios (Inst); AstraZeneca/UK (Inst); Carrick Therapeutics (Inst); Janssen Oncology (Inst); MSD Oncology; Nanoco (Inst); Novocure (Inst); Orion; Orion (Inst); Roche (Inst); Scancell (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Michelle Collinson
Research Funding - AstraZeneca
 
Elizabeth Plummer
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Sanofi/Aventis
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Benevolent AI; Biosceptre; Bristol-Myers Squibb/Medarex; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Genmab; Immunocore; Incyte; Medivir; Nerviano Medical Sciences; Novartis; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
Other Relationship - Alligator Bioscience; AstraZeneca; GlaxoSmithKline; Sotio
 
Christian Ottensmeier
Stock and Other Ownership Interests - NEUVOGEN
Honoraria - Delcath Systems; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; NEUVOGEN
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme; Roche
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Merck Sharp & Dohme (Inst); PsiOxus Therapeutics (Inst); Scancell (Inst); Touchlight Genetics (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - patents on modulation of T cell function
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Delcath Systems
Other Relationship - Transgene
 
Shobha Silva
No Relationships to Disclose
 
Jane Hook
Research Funding - MSD; Regeneron
 
Brindley Hapuarachi
No Relationships to Disclose
 
Matthew Wheater
Honoraria - Delcath Systems; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; bristol-Myers Squibb; Delcath systems; Ipsen
Research Funding - AVEO (Inst); Bristol-Myers Squibb/Medarex (Inst); Delcath Systems (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); MSD (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Delcath Systems; Ipsen
 
Miranda Payne
Employment - GenesisCare
Honoraria - Bristol-Myers Squibb; L'Oreal; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; L'Oreal; Regeneron
Speakers' Bureau - Bristol-Myers Squibb; L'Oreal; Regeneron
Travel, Accommodations, Expenses - Pierre Fabre
 
Olabode Oladipo
Consulting or Advisory Role - Bristol-myers squibs UK
 
Ashita Waterston
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Galina Velikova
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Novartis; Pfizer; Roche UK; Sanofi; Seagen
Speakers' Bureau - Novartis; Pfizer
Research Funding - IQVIA (Inst)
Travel, Accommodations, Expenses - Novartis; Roche UK
Other Relationship - University of Leeds
 
Ferdia Gallagher
Consulting or Advisory Role - Pharming NV (I)
Speakers' Bureau - Pharming NV (I)
Research Funding - AstraZeneca (Inst); GE Healthcare (Inst); NVision (Inst)
Travel, Accommodations, Expenses - Pharming NV (I)
 
David M. Meads
Consulting or Advisory Role - PHMR
 
Sue Bell
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Innovative Medicine (Inst); Johnson & Johnson (Inst)
 
Natasha Greatorex
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - Abbvie (Inst); Janssen (Inst)
 
Eszter Katona
Research Funding - GlaxoSmithKline (Inst); Pierre Fabre (Inst)
 
Janine Bestall
No Relationships to Disclose
 
Susanna Daniels
No Relationships to Disclose
 
Philippa Corrie
Honoraria - AstraZeneca; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Amgen; Anocca; Astellas Pharma; Bristol-Myers Squibb; IO Biotech; Iovance Biotherapeutics; Merck Sharp & Dohme; Microbiotica; Pierre Fabre; Scancell Ltd.; Sun Pharma
Speakers' Bureau - Merck Sharp & Dohme; Pierre Fabre
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck